Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Replacement: Form 8 (OPD) - Instem plc

5 Sep 2023 18:00

RNS Number : 4754L
Instem plc
05 September 2023
 

Amendment: Form 8 (OPD) - Instem plc

 

The following amended announcement corrects the date in section 1(e) to be 4 September 2023 and the date of disclosure to be 5 September 2023 in the Form 8 (OPD) announcement released at 4.15 p.m. on 5 September 2023 (under RNS no. 4634L)

 

The full amended version is below:

 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Instem plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Instem plc

(d) Is the discloser the offeror or the offeree?

OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

4 September 2023

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

0.00

Nil

0.00

(2) Cash-settled derivatives:

 

Nil

0.00

Nil

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Nil

0.00

Nil

0.00

 

TOTAL:

Nil

0.00

Nil

0.00

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

None

Details, including nature of the rights concerned and relevant percentages:

N/A

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

 

A) Holdings of ordinary shares by directors of Instem plc and their close relatives:

 

Name

No. Ordinary Shares Held

% of total issued share capital carrying voting rights

David Gare*

1,326,865

5.79%

Phil Reason

770,714

3.36%

Nigel Goldsmith

10,000

0.04%

 

*Includes holdings of Deborah Walker and Michael Gare and shares held via DG 2008 Discretionary Settlement Trust (of which David Gare and Norma Gare are trustees)

 

B) The directors of the Company have the following rights to subscribe for the following relevant Instem plc securities under the share options plans:

 

Name

Date of Grant

Vesting period

Latest Exercisable Date

Exercise price (£)

No. of options outstanding

Phil Reason

26/06/2020

3 years

15/03/2024

Nil

76,000

Phil Reason

16/04/2021

3 years

15/03/2025

Nil

4,387

Phil Reason

27/09/2021

3 years

15/03/2025

Nil

25,000

Phil Reason

02/03/2022

3 years

15/03/2026

Nil

4,833

Nigel Goldsmith

29/07/2015

3 years

28/07/2025

0.10

62,500

Nigel Goldsmith

22/02/2018

3 years

22/02/2028

Nil

80,000

Nigel Goldsmith

26/06/2020

3 years

26/06/2030

Nil

74,000

Nigel Goldsmith

16/04/2021

3 years

01/01/2031

Nil

3,031

Nigel Goldsmith

27/09/2021

3 years

27/09/2031

Nil

25,000

Nigel Goldsmith

02/03/2022

3 years

01/01/2032

Nil

2,165

 

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

5 September 2023

Contact name:

Nigel Goldsmith, Chief Financial Officer

Telephone number:

+44 17 8582 5608

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEEUPUAABUPWGQA
Date   Source Headline
25th Feb 201610:17 amRNSHolding(s) in Company
23rd Feb 20161:32 pmRNSResult of General Meeting and Director Dealings
12th Feb 20167:00 amRNSInvestor Presentation
5th Feb 20164:47 pmRNSIssue of Equity and Total Voting Rights
4th Feb 20167:00 amRNSDirector/PDMR Shareholding
3rd Feb 20167:00 amRNSPlacing, Posting of Circular and Notice of GM
25th Jan 20167:00 amRNSInnovators & Investors Forum
13th Jan 20167:00 amRNSTrading Update
23rd Dec 20151:15 pmRNSDirector Shareholding and Other Holdings
8th Dec 20153:53 pmRNSIssue of Equity and Total Voting Rights
1st Dec 20157:00 amRNSLogos Earn Out, Issue of Equity and TVR
30th Nov 20155:59 pmRNSHolding(s) in Company
29th Sep 20157:00 amRNSHalf Yearly Report
6th Aug 201511:55 amRNSAdmission of Ordinary Shares
3rd Aug 20157:00 amRNSLogos Third Earn Out Payment & Total Voting Rights
30th Jul 20157:00 amRNSTrading Update and Notice of Interim Results
29th Jul 20157:01 amRNSGrants Under the Long Term Incentive Plan
23rd Jun 20157:00 amRNSInvestor Teach-in
21st May 20154:39 pmRNSHolding(s) in Company
19th May 20151:16 pmRNSResult of AGM
14th May 20157:00 amRNSInstem ALPHADAS Contract Wins
27th Apr 20159:16 amRNSPosting of Annual Report and Notice of AGM
30th Mar 20157:00 amRNSFinal Results
16th Mar 20157:00 amRNSNotice of Results
13th Feb 20157:00 amRNSPerceptive Instruments Earn Out Payment
27th Jan 20157:01 amRNSInnovators & Investors Forum (London)
12th Jan 20157:00 amRNSTrading Update and Notice of Results
23rd Dec 201411:52 amRNSHolding(s) in Company
18th Dec 20147:00 amRNSWIL Research Contract Extension
10th Nov 20147:00 amRNSCentrus-submit Contract Wins
24th Sep 20147:00 amRNSUnaudited Interim Results
5th Sep 20147:00 amRNSNotice of Results
13th Aug 201410:27 amRNSHolding(s) in Company
1st Aug 20147:00 amRNSLogos Second Earn Out Payment
16th Jul 20147:00 amRNSTwo contract wins in Asia-Pacific
21st May 201411:45 amRNSResult of AGM
1st May 20147:00 amRNSContract win
25th Apr 20147:00 amRNSPosting of Annual Report and Notice of AGM
26th Mar 20147:01 amRNSUS Government Contract Extension
26th Mar 20147:00 amRNSFinal Results
6th Mar 20147:00 amRNSNotice of Results
20th Feb 20147:00 amRNSThree-Year SaaS Contract with Leading Pharma
7th Feb 20141:05 pmRNSHolding(s) in Company
3rd Feb 20147:00 amRNSLogos Initial Earn Out Payment
8th Jan 20147:00 amRNSTrading Update and Notice of Results
22nd Nov 20137:00 amRNSAcquisition and Trading Update
9th Oct 20137:00 amRNSAppointment of VP Global Sales
25th Sep 20137:00 amRNSHalf Yearly Report
15th Aug 20137:00 amRNSNotice of Results
2nd Jul 20137:00 amRNSFirst Contract Win for Instem Clinical

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.